Go Pro
→ A Simple Guide to Options Trading While It's Still Free (From True Market Insiders) (Ad)tc pixel
NASDAQ:SCLX

Scilex Q3 2024 Earnings Report

Scilex logo
$5.28 -0.07 (-1.31%)
As of 09/3/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Scilex EPS Results

Actual EPS
-$6.30
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scilex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scilex Announcement Details

Quarter
Q3 2024
Date
1/17/2025
Time
After Market Closes
Conference Call Date
Friday, January 17, 2025
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Scilex's Q3 2024 Quarterly reportQuarterly report
(10-Q)

Scilex Earnings Headlines

Scilex (NASDAQ:SCLX) Stock Rating Lowered by Wall Street Zen
August 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30989291
Scilex (SCLX) to Post Quarterly Earnings on Wednesday
August 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30983396
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.tc pixel
 |  Investors Alley (Ad)
Scilex Establishes $20 Million Credit Facility for Vivasor
August 12, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scilex-establishes-20-million-credit-facility-for-vivasor?utm_source=marketbeat.com&utm_medium=referral
Scilex Announces Strategic Sale of Vivasor Preferred Shares
July 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scilex-announces-strategic-sale-of-vivasor-preferred-shares?utm_source=marketbeat.com&utm_medium=referral
Scilex Holding Company
July 16, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/SCLX
See More Scilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scilex and other key companies, straight to your email.

About Scilex

Scilex (NASDAQ:SCLX) Holdings, Inc. (NASDAQ: SCLX) is a specialty pharmaceutical company focused on non-opioid treatments for chronic pain. The firm’s principal commercial product, ZTlido®, is a lidocaine topical system approved by the U.S. Food and Drug Administration for the management of post-herpetic neuralgia and certain peripheral neuropathic pain conditions. By leveraging a proprietary drug delivery platform, Scilex aims to improve patient comfort and safety compared to traditional oral analgesics.

In addition to marketing ZTlido® in the United States, Scilex is advancing other pain management assets through clinical development and regulatory pathways. The company’s pipeline includes additional topical and localized therapies designed to address a range of acute and chronic pain indications without the abuse potential associated with opioid medications. Scilex pursues both in-house research and selective licensing partnerships to broaden its offering.

Headquartered in San Diego, California, Scilex operates primarily in the U.S. market, where it works with healthcare providers, specialty pharmacies and distributors to ensure patient access to its products. The company’s management team brings experience in pharmaceutical development, regulatory affairs and commercial operations, supporting Scilex’s strategy of targeted growth within the pain therapeutics space.

View Scilex Profile
Earnings Tools